Profile data is unavailable for this security.
About the company
Venus Remedies Limited is a research-driven pharmaceutical company. The Company is a global injectable manufacturer. It manufactures products catering to critical care segments such as antimicrobial resistance, anti-cancer, Anti-infective, Neurology, Skin and Wound Care, and Pain Management. With a diverse portfolio of products, the Company is dedicated to revolutionizing patient care through its specialized therapeutic segments such as anti-infective (antibiotics), oncology, neurology, pain management, and skin & wound care. The Company operates only in one business segment: Pharmaceutical Formulation and is engaged in manufacturing and trading of medicines. Its focus therapy areas include medicine, surgery, neuro and orthopedics. The Company’s brands include Potentox, Vancoplus Combi, Tobracef, Supime, Zydotum, Neurotol, Trois, Septiloc, Mucomelt, and others. It has three manufacturing facilities: Panchkula and Baddi in India and Werne in Germany.
- Revenue in INR (TTM)7.00bn
- Net income in INR762.95m
- Incorporated1989
- Employees1.30k
- LocationVenus Remedies Ltd51-52, Industrial Area, Phase-1PANCHKULA 134113IndiaIND
- Phone+91 1 722933090
- Fax+91 1 722565566
- Websitehttps://www.venusremedies.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accent Microcell Ltd | 2.78bn | 346.64m | 7.84bn | 192.00 | 21.46 | 3.14 | 20.16 | 2.82 | 15.24 | 15.24 | 122.20 | 104.07 | 1.12 | 4.14 | 5.32 | 14,474,330.00 | 13.99 | -- | 15.95 | -- | 39.96 | -- | 12.47 | -- | 3.01 | 76.48 | 0.0046 | -- | 7.77 | -- | 9.60 | -- | -- | -- |
| Remus Pharmaceuticals Ltd | 7.48bn | 325.59m | 8.07bn | 68.00 | 22.02 | 2.63 | 18.35 | 1.08 | 31.11 | 31.11 | 701.20 | 260.51 | 1.89 | 9.07 | 7.21 | 109,981,700.00 | 10.44 | 14.37 | 18.44 | 28.60 | 13.01 | 19.39 | 5.51 | 8.39 | 1.07 | 35.59 | 0.0452 | 3.59 | 191.93 | 120.44 | 34.98 | 104.56 | 48.07 | -- |
| Anuh Pharma Ltd | 7.68bn | 418.22m | 8.19bn | 295.00 | 19.57 | -- | 15.47 | 1.07 | 4.17 | 4.17 | 76.65 | -- | -- | -- | -- | 26,023,040.00 | -- | 10.41 | -- | 17.00 | 22.25 | 23.95 | 5.45 | 7.35 | -- | 116.27 | -- | 26.59 | 2.24 | 16.60 | -21.16 | 27.05 | -10.78 | 16.89 |
| Themis Medicare Ltd | 3.37bn | -174.06m | 8.38bn | 1.76k | -- | -- | -- | 2.49 | -1.89 | -1.89 | 36.52 | -- | -- | -- | -- | 1,917,083.00 | -- | 10.17 | -- | 14.38 | 62.56 | 60.61 | -5.16 | 13.52 | -- | -3.71 | -- | 9.36 | 6.22 | 15.00 | -31.46 | 3.78 | 21.58 | 23.36 |
| Sigachi Industries Ltd | 5.06bn | -550.46m | 8.82bn | 1.10k | -- | 1.74 | -- | 1.74 | -1.46 | -1.46 | 13.20 | 13.29 | 0.6316 | 2.40 | 2.80 | 4,624,222.00 | -6.70 | 12.29 | -9.77 | 16.21 | 52.83 | 51.93 | -10.62 | 14.80 | 1.27 | 5.53 | 0.2436 | 4.23 | 22.38 | 28.55 | 21.66 | 27.91 | 48.87 | -- |
| Wanbury Ltd | 6.58bn | 646.86m | 9.00bn | 1.38k | 13.47 | -- | 11.37 | 1.37 | 19.13 | 19.13 | 194.16 | -- | -- | -- | -- | 4,758,967.00 | -- | 8.87 | -- | 101.40 | 55.07 | 41.82 | 9.84 | 5.62 | -- | 2.97 | -- | -- | 4.15 | 10.29 | -45.44 | -13.88 | 44.32 | -- |
| Venus Remedies Ltd | 7.00bn | 762.95m | 10.01bn | 1.30k | 13.12 | -- | 10.02 | 1.43 | 57.10 | 57.10 | 523.77 | -- | -- | -- | -- | 5,391,957.00 | -- | 6.67 | -- | 8.08 | 47.02 | 37.62 | 10.90 | 6.87 | -- | 1,849.19 | -- | -- | 7.72 | 13.81 | 59.05 | -- | 18.36 | -- |
| Sakar Healthcare Ltd | 2.31bn | 252.21m | 10.77bn | 342.00 | 42.25 | -- | 22.28 | 4.66 | 11.45 | 11.45 | 104.95 | -- | -- | -- | -- | 6,750,901.00 | -- | 4.73 | -- | 5.64 | 52.54 | 45.55 | 10.92 | 9.87 | -- | 3.66 | -- | -- | 15.80 | 16.44 | 49.96 | 12.71 | 19.34 | -- |
| Beta Drugs Ltd | 3.86bn | 464.68m | 11.27bn | 399.00 | 16.01 | 5.10 | 18.40 | 2.92 | 69.72 | 65.19 | 509.33 | 218.94 | 0.986 | 3.64 | 3.48 | 9,665,303.00 | 11.88 | 15.08 | 16.29 | 21.53 | 39.79 | 40.30 | 12.05 | 12.72 | 2.45 | 5.13 | 0.3974 | 0.00 | 22.54 | 31.89 | 28.96 | 37.92 | 19.23 | -- |
| Bajaj Healthcare Ltd | 6.12bn | 523.16m | 11.38bn | 904.00 | 22.32 | -- | 14.27 | 1.86 | 16.15 | 15.36 | 188.83 | -- | -- | -- | -- | 6,774,850.00 | -- | 7.07 | -- | 13.07 | 46.31 | 37.17 | 8.54 | 8.22 | -- | 2.92 | -- | 5.83 | 14.61 | 5.76 | 399.64 | 11.21 | -12.65 | -- |
| IND Swift Laboratories Ltd | 9.64bn | 2.75bn | 11.72bn | 1.25k | 3.75 | -- | 3.64 | 1.22 | 38.28 | 38.28 | 122.91 | -- | -- | -- | -- | 7,738,014.00 | -- | 8.65 | -- | 10.59 | 51.55 | 40.96 | 28.56 | 14.35 | -- | -3.35 | -- | 0.00 | -56.15 | -6.35 | -40.50 | -- | 41.97 | -- |
| Jagsonpal Pharmaceuticals Ltd | 2.82bn | 409.03m | 11.73bn | 1.40k | 28.87 | -- | 23.30 | 4.16 | 6.07 | 6.07 | 41.76 | -- | -- | -- | -- | 2,012,738.00 | -- | 14.71 | -- | 17.26 | 63.66 | 60.59 | 14.53 | 12.54 | -- | 44.64 | -- | 39.88 | 28.76 | 11.13 | 146.45 | 47.72 | -28.44 | 65.72 |
| Lincoln Pharmaceuticals Ltd | 6.52bn | 878.34m | 12.33bn | 1.85k | 14.04 | -- | 12.11 | 1.89 | 43.86 | 43.86 | 325.55 | -- | -- | -- | -- | 3,518,272.00 | -- | 13.22 | -- | 15.46 | 53.64 | 50.82 | 13.47 | 14.56 | -- | 77.35 | -- | 3.32 | 7.35 | 10.03 | -11.74 | 9.87 | 20.13 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Acadian Asset Management LLCas of 31 Dec 2025 | 147.50k | 1.10% |
| Victory Capital Management, Inc. (Investment Management)as of 31 Dec 2025 | 2.05k | 0.02% |
